M&A Deal Summary

Alfasigma Acquires Intercept

On September 26, 2023, Alfasigma acquired life science company Intercept

Acquisition Highlights
  • This is Alfasigma’s 2nd transaction in the Life Science sector.
  • This is Alfasigma’s 1st transaction in the United States.
  • This is Alfasigma’s 1st transaction in New Jersey.

M&A Deal Summary

Date 2023-09-26
Target Intercept
Sector Life Science
Buyer(s) Alfasigma
Deal Type Add-on Acquisition
Advisor(s) Barclays Investment Bank
Centerview Partners (Financial)
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

Intercept

Morristown, New Jersey, United States
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). Intercept is based in Morristown, New Jersey

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Alfasigma

Bologna, Italy

Category Company
Sector Life Science
Revenue 1.0B EUR (2021)
DESCRIPTION

Alfasigma is a multinational pharmaceutical company with 3 production plants in Italy and 2 abroad, and on-site presence in 17 markets plus an indirect presence in about 70 countries. Alfasigma is based in Bologna, Italy.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: New Jersey M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2023 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-02 Sofar

Trezzano Rosa, Italy

Sofar is an Italian pharmaceutical company active in the research, production, and marketing of drugs, medical devices, and dietary supplements -with a long-standing tradition and well-known to professionals and patients. Sofar was formed in 1968 and is based in Trezzano Rosa, Italy.

Buy -